IR-783
Based on 4 publication(s) in Google Scholar
IR-783 (ADS 780WS) is a heptamethine cyanine dye. IR-783 induces Mitochondrial membrane potential loss, ATP depletion, mitochondrial permeability transition pore opening, Cytochrome c release and Apoptosis in breast cancer cells. IR-783 promotes the translocation of Drp1 from the cytosol to mitochondria. IR-783 increases the expression of mitochondrial fission proteins such as MFF and Fission-1. IR-783 possesses imaging, cancer-targeting and anticancer properties. IR-783 exerts anticancer effects against breast cancer. IR-783 can be used in breast cancer-related research.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 115970-66-6
- Formula: C38H46ClN2NaO6S2
- Molecular Weight:749.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) IR-783
More
Biological Activity
IR-783 (20-100 μM; 24 h for membrane potential assays) induces intracellular ATP depletion and loss of mitochondrial membrane potential in breast cancer MDA-MB-231 cells[1].
IR-783 (5-120 μM; 6-72 h) selectively inhibits the viability of breast cancer MDA-MB-231 cells in a dose- and time-dependent manner, but exerts no effect on normal hepatocyte LO2 cells[1].
IR-783 (20-100 μM; 24 h) induces apoptosis in breast cancer MDA-MB-231 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human breast cancer MDA-MB-231 cells, human normal hepatocyte LO2 cells
-
Concentration:5-120 μM (24 h incubation); 40 μM (time-course incubation)
-
Incubation Time:6-72 h (40 μM concentration); 24 h (5-120 μM concentrations)
-
Result:Decreased MDA-MB-231 cell viability in a dose- and time-dependent manner, with significant reductions at all tested concentrations and time points relative to control.
Showed no apparent effect on LO2 cell viability even at 120 μM.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:20-100 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of apoptotic MDA-MB-231 cells in a dose-dependent manner.
Increased cleaved-caspase-3 levels in a dose-dependent fashion.
Increased cleaved-poly ADP-ribose polymerase (C-PARP) levels relative to control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (female, 5 weeks old)[1]
-
Dosage:20 mg/kg
-
Administration:i.v.; daily; 4 weeks
-
Result:Inhibited tumour growth significantly after 3 weeks of exposure compared to controls (P < .05).
Showed no statistically significant changes in body weight compared to controls.
Induced no morphological differences in liver and kidney tissues, indicating low liver and kidney toxicity.
Increased numbers of TUNEL-positive cells in tumour tissue.
Increased immunoreactivity for cleaved-caspase-3 in tumour tissue.
Increased Drp1 expression in mitochondrial fractions of tumour tissue.
Increased colocalization of Drp1 and the mitochondrial marker TOM20 in tumour tissue.
Chemical Information
-
CAS No. 115970-66-6
-
Appearance Solid
-
Molecular Weight 749.35
-
Formula C38H46ClN2NaO6S2
-
Color Green to dark green
-
SMILES
O=[S](CCCCN(/C1=C\C=C(CCC2)\C(Cl)=C2/C=C/C(C3(C)C)=[N+](C4=CC=CC=C34)CCCC[S](=O)([O-])=O)C5=CC=CC=C5C1(C)C)(O[Na])=O
-
Synonyms
ADS 780WS
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
ACS Appl Mater Interfaces
2026 Jan 25. PMID: 41582522 -
-
Solvent & Solubility
DMSO : 116.67 mg/mL (155.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3345 mL | 6.6724 mL | 13.3449 mL | 33.3622 mL |
| 5 mM | 0.2669 mL | 1.3345 mL | 2.6690 mL | 6.6724 mL | |
| 10 mM | 0.1334 mL | 0.6672 mL | 1.3345 mL | 3.3362 mL | |
| 15 mM | 0.0890 mL | 0.4448 mL | 0.8897 mL | 2.2241 mL | |
| 20 mM | 0.0667 mL | 0.3336 mL | 0.6672 mL | 1.6681 mL | |
| 25 mM | 0.0534 mL | 0.2669 mL | 0.5338 mL | 1.3345 mL | |
| 30 mM | 0.0445 mL | 0.2224 mL | 0.4448 mL | 1.1121 mL | |
| 40 mM | 0.0334 mL | 0.1668 mL | 0.3336 mL | 0.8341 mL | |
| 50 mM | 0.0267 mL | 0.1334 mL | 0.2669 mL | 0.6672 mL | |
| 60 mM | 0.0222 mL | 0.1112 mL | 0.2224 mL | 0.5560 mL | |
| 80 mM | 0.0167 mL | 0.0834 mL | 0.1668 mL | 0.4170 mL | |
| 100 mM | 0.0133 mL | 0.0667 mL | 0.1334 mL | 0.3336 mL |
IR-783 Related Classifications
HY-139109 Related Classifications
Powered by Bioz